Thrombosis Research
Volume 125 , Pages S60-S62 , April 2010

Long-term expression of canine FVIIa in hemophilic dogs

  • Paris Margaritis

      Affiliations

    • Corresponding Author InformationThe Children's Hospital of Philadelphia, Abramson Research Center, Rm. 302, 3615 Civic Center Blvd., Philadelphia, PA 19104, U.S.A. Tel.: +1 267 426 7262; fax: +1 215 590 3660.

References 

  1. Leissinger CA. Inhibitor development in patients with hemophilia: an overview. Semin Hematol. 2006;43(2 Suppl 4):S1–S2
  2. Margaritis P, Arruda VR, Aljamali M, Camire RM, Schlachterman A, High KA. Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII. J Clin Invest. 2004;7:1025–1031
  3. Janson TL, Stormorken H, Prydz H. Species specificity of tissue thromboplastin. Haemostasis. 1984;14:440–444
  4. Kadish JL, Wenc KM, Dvorak HF. Tissue factor activity of normal and neoplastic cells: quantitation and species specificity. J Natl Cancer Inst. 1983;70:551–557
  5. Petersen LC, Norby PL, Branner S, Sorensen BB, Elm T, Stennicke HR, et al. Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study. Thromb Res. 2005;116:75–85
  6. Aljamali MN, Margaritis P, Schlachterman A, Tai SJ, Roy E, Bunte R, et al. Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality. J Clin Invest. 2008;118:1825–1834
  7. Russell KE, Olsen EH, Raymer RA, Merricks EP, Bellinger DA, Read MS, et al. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs. Blood. 2003;102:4393–4398
  8. Brinkhous K, Sandberg H, Widlund L, Read M, Nichols T, Sigman J, et al. Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII. Semin Thromb Hemost. 2002;28:269–272
  9. Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. Proc Natl Acad Sci U S A. 1989;86:1382–1386
  10. Brinkhous KM, Sandberg H, Garris JB, Mattsson C, Palm M, Griggs T, et al. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A. 1985;82:8752–8756
  11. Brinkhous KM, Shanbrom E, Roberts HR, Webster WP, Fekete L, Wagner RH. A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors. JAMA. 1968;205:613–617
  12. Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, et al. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. Blood. 1996;88:2603–2610
  13. Jiang H, Lillicrap D, Patarroyo-White S, Liu T, Qian X, Scallan CD, et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood. 2006;108:107–115
  14. Mount JD, Herzog RW, Tillson DM, Goodman SA, Robinson N, McCleland ML, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood. 2002;99:2670–2676
  15. Sarkar R, Mucci M, Addya S, Tetreault R, Bellinger DA, Nichols TC, et al. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice. Hum Gene Ther. 2006;17:427–439
  16. Wang L, Calcedo R, Nichols TC, Bellinger DA, Dillow A, Verma IM, et al. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood. 2005;105:3079–3086
  17. Callan MB, Aljamali MN, Margaritis P, Griot-Wenk ME, Pollak ES, Werner P, et al. A novel missense mutation responsible for factor VII deficiency in research Beagle colonies. J Thromb Haemost. 2006;4:2616–2622
  18. Margaritis P, Roy E, Aljamali MN, Downey HD, Giger U, Zhou S, et al. Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood. 2009;113:3682–3689
  19. Nathwani AC, Gray JT, Ng CY, Zhou J, Spence Y, Waddington SN, et al. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood. 2006;107:2653–2661
  20. Wu Z, Sun J, Zhang T, Yin C, Yin F, Van Dyke T, et al. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther. 2008;16:280–289
  21. Persson E, Bak H, Olsen OH. Substitution of valine for leucine 305 in factor VIIa increases the intrinsic enzymatic activity. J Biol Chem. 2001;276:29195–29199
  22. Persson E, Bak H, Ostergaard A, Olsen OH. Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement. Biochem J. 2004;379:497–503
  23. Harvey SB, Stone MD, Martinez MB, Nelsestuen GL. Mutagenesis of the gamma-carboxyglutamic acid domain of human factor VII to generate maximum enhancement of the membrane contact site. J Biol Chem. 2003;278:8363–8369
  24. Nelsestuen GL, Stone M, Martinez MB, Harvey SB, Foster D, Kisiel W. Elevated function of blood clotting factor VIIa mutants that have enhanced affinity for membranes. Behavior in a diffusion-limited reaction. J Biol Chem. 2001;276:39825–39831
  25. Lauritzen B, Tranholm M, Ezban M. rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats. J Thromb Haemost. 2009;7:651–657
  26. Tranholm M, Kristensen K, Kristensen AT, Pyke C, Rojkjaer R, Persson E. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood. 2003;102:3615–3620
  27. Moss J, Scharling B, Ezban M, Sorensen TM. Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects. J Thromb Haemost. 2009;7:299–305

PII: S0049-3848(10)00093-9

doi: 10.1016/j.thromres.2010.01.040

Thrombosis Research
Volume 125 , Pages S60-S62 , April 2010

Article Tools